{
    "nctId": "NCT01246427",
    "briefTitle": "Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer",
    "officialTitle": "Placebo-controlled Evaluation of the Homeopathic Drug BRN01 for the Treatment of Hot Flashes in Women With Non Metastatic Breast Cancer Treated by Adjuvant Hormonal Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 138,
    "primaryOutcomeMeasure": "Evaluation of BRN01 efficacy in reducing hot flash score after 4 weeks of treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patient aged \u2265 18 years\n* Women with histologically proven non metastatic breast cancer\n* ECOG PS \u2264 1\n* Patient receiving adjuvant hormonal therapy for at least 1 month (aromatase inhibitor or Tamoxifen \u00b1 ovarian function suppression (Luteinizing Hormone Releasing Hormone agonist (LH-RH agonist), ovariectomy...))\n* Patient complaining of hot flashes with moderate to severe intensity, affecting quality of life, for at least 1 month before inclusion\n* Patient agreement not to start another hot flash treatment during the study (allopathic treatment, E vitamin, dietary supplement, phytotherapy, acupuncture...)\n* Patient able to understand, read and write French\n* Mandatory affiliation with a health insurance system\n* Signed, written informed consent\n\nExclusion Criteria:\n\n* Ongoing chemotherapy or radiotherapy, or treatment planned to begin during the study\n* Patient with a condition known to induce hot flashes such as hyperthyroidism, diabetes, adrenal tumor, enteric carcinoid tumor, mastocytosis...\n* Patient with severe renal failure, severe hepatic failure, or cardiovascular disease\n* Patient with one of the following contraindications:\n\n  * known hypersensitivity to one of the components of the study drug\n  * galactose, fructose intolerance\n  * Lapp lactase deficiency, isomaltase invertase deficiency\n  * Glucose or galactose malabsorption syndrome\n* Follow up impossible because of social, familial, geographical or psychological reasons\n* Patient suspected of poor compliance with protocol or treatment\n* Participation in another biomedical research trial in the same indication, or administration of an experimental drug in the same indication in the 30 days before inclusion",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}